epoetin alfa


Duopharma (M)


Concise Prescribing Info
Epoetin α
Anaemia associated w/ chronic renal failure in haemo- & predialysis adults & haemodialysis paed. Facilitate autologous blood collection w/in predeposit program in patients scheduled for major elective surgery.
Dosage/Direction for Use
IV Haemodialysis Adult & childn Correction phase: 50 IU/kg 3 times/wk, may be increased in increments of 25 IU/kg 3 times/wk for at least 4-wk intervals. Maintenance phase: Adult Recommended total wkly dose: 75-300 IU/kg. Childn >30 kg 30-100 IU/kg 3 times/wk, 10-30 kg 60-150 IU/kg 3 times/wk, <10 kg 75-100 IU/kg 3 times/wk. Autologous pre-donation program in surgery 600 IU/kg IV twice/wk for 3 wk prior to surgery. Patient who require lesser degree of erythropoietin stimulation 150-300 IU/kg twice wkly.
Hypersensitivity to epoetin α or mammalian cell-derived products. Uncontrolled HTN. Ab-mediated pure red cell aplasia (PRCA). Patients scheduled for elective surgery & not participating in autologous blood pre-donation program who have severe coronary, peripheral arterial, carotid or cerebrovascular diseases eg, patients w/ recent MI or CVA. Surgical patients who cannot receive adequate antithrombotic prophylaxis or treatment.
Special Precautions
Hypersensitivity. Not to be used as IV infusion or SC inj. Not for management of anemia associated w/ hepatitis C. Discontinue use if Stevens-Johnson syndrome/toxic epidermal necrolysis is suspected. Venous & arterial thromboses & embolism eg, DVT, pulmonary emboli, retinal thrombosis & MI; CVA eg, cerebral infarction & haemorrhage, transient ischaemic attacks. HTN; hypertensive crisis w/ encephalopathy & seizures; migraine-like headache; PRCA; epilepsy, history of seizures, conditions associated to seizure activity eg, CNS infections & brain metastases; thrombocythaemia; porphyria. Routine vol replacement in autologous pre-donation programme. Monitor Hb, BP, platelet counts & serum electrolytes regularly. Ensure adequate Fe stores & supplementation in other causes of anaemia. May affect ability to drive & use machines. Hepatic dysfunction. Chronic renal failure. Pregnancy & lactation.
Adverse Reactions
Upper resp tract infection, nasopharyngitis, pneumonia, arteriovenous fistula site infection; diarrhoea, constipation, gastritis, upper abdominal pain & gastric haemorrhage; procedural hypotension, arteriovenous fistula site complication & thrombosis; fluid overload, hyperkalaemia; HTN, inadequately controlled BP, hypertensive crisis; pyrexia; muscle spasms; cough, rhinorrhoea; renal transplant; dizziness, cerebral infarction, intracranial haemorrhage; rash.
Drug Interactions
Monitor cyclosporine blood levels.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Erysaa soln for inj 2,000 IU/0.5 mL
Erysaa soln for inj 4,000 IU/0.4 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in